article thumbnail

Guaranteeing resilience in vaccine manufacturing

European Pharmaceutical Review

There has been a steady stream of developments in the vaccine manufacturing space throughout 2023. A notable milestone was Moderna’s announcement in April that it had, following finalisation of a ten-year strategic partnership with the UK Government, commenced construction of its mRNA vaccine manufacturing technology centre.

article thumbnail

BioNTech to acquire GMP manufacturing facility in Singapore

Pharmaceutical Technology

BioNTech’s Singapore affiliate BioNTech Pharmaceuticals Asia Pacific has signed an agreement with Novartis Singapore Pharmaceutical Manufacturing to acquire a GMP-certified manufacturing site in the country. . It also has the potential for extension into the manufacturing of other drug classes such as cell therapies. .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Key developments in pharmaceutical manufacturing – September 2023

European Pharmaceutical Review

September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. Importantly, each site features advanced technologies to support development and manufacture of these therapeutics. Materials and financing costs are high and squeezing manufacturers and their customers alike.

article thumbnail

Juno Pharmaceuticals buys Omega Laboratories

Pharmaceutical Technology

Juno Pharmaceuticals Canada has purchased Omega Laboratories, a specialist injectable pharmaceutical manufacturer in Canada, for an undisclosed sum. The merged entity represents one of the biggest specialist generic injectable operations in Canada with local manufacturing facilities.

article thumbnail

Vaccine producers promise equal access in future pandemics

European Pharmaceutical Review

Three trade bodies representing vaccine creators and manufacturers are endorsing The Berlin Declaration framework , a proposal that outlines how the industry would reserve an allocation of real-time vaccine production for swift distribution to priority populations in lower-income countries in future pandemics.

article thumbnail

Strategies for Combination Therapy in Oncology: Part One – Business as Usual

PM360

From the manufacturer perspective, payer policies and legislation on combination therapy pricing are impacting global development, pricing, access, and commercialization strategies. As a result, manufacturers are increasingly opting to not launch their combination indications in certain markets. Certain markets (e.g.,

article thumbnail

Methods for strain comparison and differentiation of environmental isolates

European Pharmaceutical Review

NCIMB Ltd provides microbial identification services and curates The National Collection of Industrial, Food and Marine Bacteria – one of the culture collections that makes up the UK Biological Resource Centre Network.